Improved survival with bevacizumab in advanced cervical cancer Academic Article uri icon

Overview

MeSH Major

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols
  • Uterine Cervical Neoplasms

abstract

  • The addition of bevacizumab to combination chemotherapy in patients with recurrent, persistent, or metastatic cervical cancer was associated with an improvement of 3.7 months in median overall survival. (Funded by the National Cancer Institute; GOG 240 ClinicalTrials.gov number, NCT00803062.).

publication date

  • February 24, 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4010094

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1309748

PubMed ID

  • 24552320

Additional Document Info

start page

  • 734

end page

  • 43

volume

  • 370

number

  • 8